IBB holdings
iShares Biotechnology ETF
Positions
252 stored of 252 reported, largest first by weight
| # | Holding | ISIN | CUSIP | Weight | Value (USD) | Type | Issuer type | Country | Currency |
|---|---|---|---|---|---|---|---|---|---|
| 101 | AbCellera Biologics, Inc. | CA00288U1066 | 00288U106 | 0.143% | $13.0M | Equity (common) | Corporate | Canada | USD |
| 102 | Sarepta Therapeutics, Inc. | US8036071004 | 803607100 | 0.142% | $12.9M | Equity (common) | Corporate | United States | USD |
| 103 | Syndax Pharmaceuticals, Inc. | US87164F1057 | 87164F105 | 0.138% | $12.5M | Equity (common) | Corporate | United States | USD |
| 104 | Trevi Therapeutics, Inc. | US89532M1018 | 89532M101 | 0.135% | $12.3M | Equity (common) | Corporate | United States | USD |
| 105 | Recursion Pharmaceuticals, Inc. Recursion Pharmaceuticals, Inc., Class A | US75629V1044 | 75629V104 | 0.135% | $12.2M | Equity (common) | Corporate | United States | USD |
| 106 | Zai Lab Ltd. | US98887Q1040 | 98887Q104 | 0.132% | $12.0M | Equity (common) | Corporate | Cayman Islands | USD |
| 107 | Amylyx Pharmaceuticals, Inc. | US03237H1014 | 03237H101 | 0.130% | $11.8M | Equity (common) | Corporate | United States | USD |
| 108 | Mineralys Therapeutics, Inc. | US6031701013 | 603170101 | 0.128% | $11.6M | Equity (common) | Corporate | United States | USD |
| 109 | Fortrea Holdings, Inc. | US34965K1079 | 34965K107 | 0.127% | $11.5M | Equity (common) | Corporate | United States | USD |
| 110 | Taysha Gene Therapies, Inc. | US8776191061 | 877619106 | 0.126% | $11.5M | Equity (common) | Corporate | United States | USD |
| 111 | MBX Biosciences, Inc. | US55287L1017 | 55287L101 | 0.126% | $11.5M | Equity (common) | Corporate | United States | USD |
| 112 | Stoke Therapeutics, Inc. | US86150R1077 | 86150R107 | 0.126% | $11.5M | Equity (common) | Corporate | United States | USD |
| 113 | Iovance Biotherapeutics, Inc. | US4622601007 | 462260100 | 0.125% | $11.4M | Equity (common) | Corporate | United States | USD |
| 114 | Novocure Ltd. | JE00BYSS4X48 | Not reported | 0.122% | $11.1M | Equity (common) | Corporate | Jersey | USD |
| 115 | Grifols SA | US3984384087 | 398438408 | 0.121% | $11.0M | Equity (common) | Corporate | Spain | USD |
| 116 | AtaiBeckley, Inc. | US04650F1012 | 04650F101 | 0.120% | $10.9M | Equity (common) | Corporate | United States | USD |
| 117 | Absci Corp. | US00091E1091 | 00091E109 | 0.120% | $10.9M | Equity (common) | Corporate | United States | USD |
| 118 | Compass Pathways plc | US20451W1018 | 20451W101 | 0.119% | $10.8M | Equity (common) | Corporate | United Kingdom | USD |
| 119 | UroGen Pharma Ltd. | IL0011407140 | Not reported | 0.118% | $10.7M | Equity (common) | Corporate | Israel | USD |
| 120 | Novavax, Inc. | US6700024010 | 670002401 | 0.115% | $10.5M | Equity (common) | Corporate | United States | USD |
| 121 | Tyra Biosciences, Inc. | US90240B1061 | 90240B106 | 0.111% | $10.0M | Equity (common) | Corporate | United States | USD |
| 122 | Monte Rosa Therapeutics, Inc. | US61225M1027 | 61225M102 | 0.110% | $10.0M | Equity (common) | Corporate | United States | USD |
| 123 | Nuvation Bio, Inc. Nuvation Bio, Inc., Class A | US67080N1019 | 67080N101 | 0.109% | $9.9M | Equity (common) | Corporate | United States | USD |
| 124 | Vir Biotechnology, Inc. | US92764N1028 | 92764N102 | 0.106% | $9.7M | Equity (common) | Corporate | United States | USD |
| 125 | Immunocore Holdings plc | US45258D1054 | 45258D105 | 0.105% | $9.5M | Equity (common) | Corporate | United Kingdom | USD |
| 126 | CareDx, Inc. | US14167L1035 | 14167L103 | 0.103% | $9.4M | Equity (common) | Corporate | United States | USD |
| 127 | GH Research plc | IE000GID8VI0 | Not reported | 0.102% | $9.3M | Equity (common) | Corporate | Ireland | USD |
| 128 | MannKind Corp. | US56400P7069 | 56400P706 | 0.097% | $8.9M | Equity (common) | Corporate | United States | USD |
| 129 | Lakefront Biotherapeutics NV | US36315X1019 | 36315X101 | 0.097% | $8.8M | Equity (common) | Corporate | Belgium | USD |
| 130 | Rapport Therapeutics, Inc. | US75383L1026 | 75383L102 | 0.092% | $8.4M | Equity (common) | Corporate | United States | USD |
| 131 | Sionna Therapeutics, Inc. | US8294011080 | 829401108 | 0.090% | $8.2M | Equity (common) | Corporate | United States | USD |
| 132 | ArriVent Biopharma, Inc. | US04272N1028 | 04272N102 | 0.088% | $8.0M | Equity (common) | Corporate | United States | USD |
| 133 | Xencor, Inc. | US98401F1057 | 98401F105 | 0.087% | $7.9M | Equity (common) | Corporate | United States | USD |
| 134 | Bicara Therapeutics, Inc. | US0554771032 | 055477103 | 0.087% | $7.9M | Equity (common) | Corporate | United States | USD |
| 135 | Inhibrx Biosciences, Inc. | US45720N1037 | 45720N103 | 0.080% | $7.3M | Equity (common) | Corporate | United States | USD |
| 136 | Maze Therapeutics, Inc. | US5787841007 | 578784100 | 0.080% | $7.2M | Equity (common) | Corporate | United States | USD |
| 137 | Pharvaris NV | NL00150005Y4 | Not reported | 0.079% | $7.2M | Equity (common) | Corporate | Netherlands | USD |
| 138 | WaVe Life Sciences Ltd. | SG9999014716 | Not reported | 0.076% | $6.9M | Equity (common) | Corporate | Singapore | USD |
| 139 | Stevanato Group SpA | IT0005452658 | Not reported | 0.074% | $6.7M | Equity (common) | Corporate | Italy | USD |
| 140 | Mesoblast Ltd. | US5907174016 | 590717401 | 0.074% | $6.7M | Equity (common) | Corporate | Australia | USD |
| 141 | MeiraGTx Holdings plc | KYG596651029 | Not reported | 0.074% | $6.7M | Equity (common) | Corporate | Cayman Islands | USD |
| 142 | Corvus Pharmaceuticals, Inc. | US2210151005 | 221015100 | 0.073% | $6.7M | Equity (common) | Corporate | United States | USD |
| 143 | Kura Oncology, Inc. | US50127T1097 | 50127T109 | 0.073% | $6.6M | Equity (common) | Corporate | United States | USD |
| 144 | Septerna, Inc. | US81734D1046 | 81734D104 | 0.071% | $6.5M | Equity (common) | Corporate | United States | USD |
| 145 | Precigen, Inc. | US74017N1054 | 74017N105 | 0.070% | $6.4M | Equity (common) | Corporate | United States | USD |
| 146 | Olema Pharmaceuticals, Inc. | US68062P1066 | 68062P106 | 0.069% | $6.2M | Equity (common) | Corporate | United States | USD |
| 147 | Janux Therapeutics, Inc. | US47103J1051 | 47103J105 | 0.068% | $6.2M | Equity (common) | Corporate | United States | USD |
| 148 | Replimune Group, Inc. | US76029N1063 | 76029N106 | 0.066% | $6.0M | Equity (common) | Corporate | United States | USD |
| 149 | Zevra Therapeutics, Inc. | US4884452065 | 488445206 | 0.065% | $5.9M | Equity (common) | Corporate | United States | USD |
| 150 | Personalis, Inc. | US71535D1063 | 71535D106 | 0.064% | $5.9M | Equity (common) | Corporate | United States | USD |
| 151 | Alto Neuroscience, Inc. | US02157Q1094 | 02157Q109 | 0.064% | $5.8M | Equity (common) | Corporate | United States | USD |
| 152 | Cullinan Therapeutics, Inc. | US2300311063 | 230031106 | 0.064% | $5.8M | Equity (common) | Corporate | United States | USD |
| 153 | Theravance Biopharma, Inc. | KYG8807B1068 | Not reported | 0.064% | $5.8M | Equity (common) | Corporate | Cayman Islands | USD |
| 154 | Annexon, Inc. | US03589W1027 | 03589W102 | 0.063% | $5.8M | Equity (common) | Corporate | United States | USD |
| 155 | Zenas Biopharma, Inc. | US98937L1052 | 98937L105 | 0.063% | $5.7M | Equity (common) | Corporate | United States | USD |
| 156 | Geron Corp. | US3741631036 | 374163103 | 0.062% | $5.7M | Equity (common) | Corporate | United States | USD |
| 157 | Solid Biosciences, Inc. | US83422E2046 | 83422E204 | 0.061% | $5.5M | Equity (common) | Corporate | United States | USD |
| 158 | BioAge Labs, Inc. | US09077V1008 | 09077V100 | 0.060% | $5.5M | Equity (common) | Corporate | United States | USD |
| 159 | Arbutus Biopharma Corp. | CA03879J1003 | 03879J100 | 0.059% | $5.3M | Equity (common) | Corporate | Canada | USD |
| 160 | Castle Biosciences, Inc. | US14843C1053 | 14843C105 | 0.055% | $5.0M | Equity (common) | Corporate | United States | USD |
| 161 | Rigel Pharmaceuticals, Inc. | US7665597024 | 766559702 | 0.054% | $4.9M | Equity (common) | Corporate | United States | USD |
| 162 | Ironwood Pharmaceuticals, Inc. Ironwood Pharmaceuticals, Inc., Class A | US46333X1081 | 46333X108 | 0.052% | $4.7M | Equity (common) | Corporate | United States | USD |
| 163 | ORIC Pharmaceuticals, Inc. | US68622P1093 | 68622P109 | 0.051% | $4.7M | Equity (common) | Corporate | United States | USD |
| 164 | Savara, Inc. | US8051111016 | 805111101 | 0.051% | $4.6M | Equity (common) | Corporate | United States | USD |
| 165 | Maravai LifeSciences Holdings, Inc. Maravai LifeSciences Holdings, Inc., Class A | US56600D1072 | 56600D107 | 0.051% | $4.6M | Equity (common) | Corporate | United States | USD |
| 166 | Sana Biotechnology, Inc. | US7995661045 | 799566104 | 0.049% | $4.5M | Equity (common) | Corporate | United States | USD |
| 167 | CytomX Therapeutics, Inc. | US23284F1057 | 23284F105 | 0.049% | $4.4M | Equity (common) | Corporate | United States | USD |
| 168 | 4D Molecular Therapeutics, Inc. | US35104E1001 | 35104E100 | 0.048% | $4.4M | Equity (common) | Corporate | United States | USD |
| 169 | Phathom Pharmaceuticals, Inc. | US71722W1071 | 71722W107 | 0.048% | $4.4M | Equity (common) | Corporate | United States | USD |
| 170 | Candel Therapeutics, Inc. | US1374041093 | 137404109 | 0.047% | $4.2M | Equity (common) | Corporate | United States | USD |
| 171 | Aclaris Therapeutics, Inc. | US00461U1051 | 00461U105 | 0.045% | $4.1M | Equity (common) | Corporate | United States | USD |
| 172 | REGENXBIO, Inc. | US75901B1070 | 75901B107 | 0.044% | $4.0M | Equity (common) | Corporate | United States | USD |
| 173 | OPKO Health, Inc. | US68375N1037 | 68375N103 | 0.044% | $4.0M | Equity (common) | Corporate | United States | USD |
| 174 | Altimmune, Inc. | US02155H2004 | 02155H200 | 0.043% | $3.9M | Equity (common) | Corporate | United States | USD |
| 175 | Design Therapeutics, Inc. | US25056L1035 | 25056L103 | 0.042% | $3.8M | Equity (common) | Corporate | United States | USD |
| 176 | Allogene Therapeutics, Inc. | US0197701065 | 019770106 | 0.041% | $3.8M | Equity (common) | Corporate | United States | USD |
| 177 | Cytek Biosciences, Inc. | US23285D1090 | 23285D109 | 0.041% | $3.7M | Equity (common) | Corporate | United States | USD |
| 178 | Myriad Genetics, Inc. | US62855J1043 | 62855J104 | 0.039% | $3.6M | Equity (common) | Corporate | United States | USD |
| 179 | ARS Pharmaceuticals, Inc. | US82835W1080 | 82835W108 | 0.039% | $3.5M | Equity (common) | Corporate | United States | USD |
| 180 | Ginkgo Bioworks Holdings, Inc. Ginkgo Bioworks Holdings, Inc., Class A | US37611X2099 | 37611X209 | 0.039% | $3.5M | Equity (common) | Corporate | United States | USD |
| 181 | Contineum Therapeutics, Inc. Contineum Therapeutics, Inc., Class A | US21217B1008 | 21217B100 | 0.037% | $3.4M | Equity (common) | Corporate | United States | USD |
| 182 | Pacific Biosciences of California, Inc. | US69404D1081 | 69404D108 | 0.037% | $3.4M | Equity (common) | Corporate | United States | USD |
| 183 | C4 Therapeutics, Inc. | US12529R1077 | 12529R107 | 0.036% | $3.3M | Equity (common) | Corporate | United States | USD |
| 184 | Aura Biosciences, Inc. | US05153U1079 | 05153U107 | 0.036% | $3.2M | Equity (common) | Corporate | United States | USD |
| 185 | Sagimet Biosciences, Inc. Sagimet Biosciences, Inc., Class A | US7867001049 | 786700104 | 0.035% | $3.2M | Equity (common) | Corporate | United States | USD |
| 186 | Arvinas, Inc. | US04335A1051 | 04335A105 | 0.035% | $3.2M | Equity (common) | Corporate | United States | USD |
| 187 | Cabaletta Bio, Inc. | US12674W1099 | 12674W109 | 0.034% | $3.1M | Equity (common) | Corporate | United States | USD |
| 188 | Prothena Corp. plc | IE00B91XRN20 | Not reported | 0.034% | $3.1M | Equity (common) | Corporate | Ireland | USD |
| 189 | Alvotech SA | LU2458332611 | Not reported | 0.034% | $3.1M | Equity (common) | Corporate | Luxembourg | USD |
| 190 | Emergent BioSolutions, Inc. | US29089Q1058 | 29089Q105 | 0.032% | $2.9M | Equity (common) | Corporate | United States | USD |
| 191 | Enanta Pharmaceuticals, Inc. | US29251M1062 | 29251M106 | 0.031% | $2.8M | Equity (common) | Corporate | United States | USD |
| 192 | Neurogene, Inc. | US64135M1053 | 64135M105 | 0.031% | $2.8M | Equity (common) | Corporate | United States | USD |
| 193 | Fulgent Genetics, Inc. | US3596641098 | 359664109 | 0.029% | $2.6M | Equity (common) | Corporate | United States | USD |
| 194 | Rocket Pharmaceuticals, Inc. | US77313F1066 | 77313F106 | 0.027% | $2.5M | Equity (common) | Corporate | United States | USD |
| 195 | Prime Medicine, Inc. | US74168J1016 | 74168J101 | 0.027% | $2.5M | Equity (common) | Corporate | United States | USD |
| 196 | Vanda Pharmaceuticals, Inc. | US9216591084 | 921659108 | 0.027% | $2.5M | Equity (common) | Corporate | United States | USD |
| 197 | Kyverna Therapeutics, Inc. | US5019761049 | 501976104 | 0.026% | $2.4M | Equity (common) | Corporate | United States | USD |
| 198 | BridgeBio Oncology Therapeutics, Inc. BridgeBio Oncology Therapeutics, Inc., Class A | US1079241022 | 107924102 | 0.026% | $2.3M | Equity (common) | Corporate | United States | USD |
| 199 | Tectonic Therapeutic, Inc. | US8789721086 | 878972108 | 0.025% | $2.3M | Equity (common) | Corporate | United States | USD |
| 200 | Autolus Therapeutics plc | US05280R1005 | 05280R100 | 0.025% | $2.3M | Equity (common) | Corporate | United Kingdom | USD |